Volume 5.38 | Oct 10

Prostate Cell News 5.38 October 10, 2014
Prostate Cell News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  PCN on Twitter
SRC-2 Drives Castration-Resistant Prostate Cancer
Investigators determined that SRC-2, frequently amplified or overexpressed in patients with spreading or metastatic prostate cancer, is involved in the development of castration-resistant prostate cancer. In studies of mice, they found that overexpression or high levels of SRC-2 in prostate tissue resulted in hyperplasia of the prostate. [Press release from Baylor College of Medicine discussing online prepublication in the Journal of Clinical Investigation] Press Release | Full Article
New TeSR™-E8™ is Here For Feeder-Free Culture of Human ES Cells and iPS Cells
PUBLICATIONS (Ranked by impact factor of the journal)

ProNGF Correlates with Gleason Score and Is a Potential Driver of Nerve Infiltration in Prostate Cancer
Nerve infiltration is essential to prostate cancer progression, but the mechanism by which nerves are attracted to prostate tumors remains unknown. Scientists report that the precursor of nerve growth factor (proNGF) is overexpressed in prostate cancer and involved in the ability of prostate cancer cells to induce axonogenesis.
[Am J Pathol]

Long Noncoding RNAs as Putative Biomarkers for Prostate Cancer Detection
Scientists identified a group of differentially expressed long noncoding RNAs in prostate cancer cell lines and patient samples and further characterized six long noncoding RNAs in prostatic adenocarcinoma tissue samples and compared them with matched normal tissues. [J Mol Diagn] Abstract | Press Release

Inhibition of TGF-β/SMADs Signal by miR-155 Is Involved in Arsenic Trioxide-Induced Anti-Angiogenesis in Prostate Cancer
Arsenic trioxide attenuated the angiogenic ability by microRNA-155 (miR-155)-mediated inhibition of transforming growth factor beta (TGF-β)/SMADs signal pathway in human prostate cancer PC-3 and LNCaP cells in vitro and in vivo. [Cancer Sci] Abstract

Short Hairpin RNA Library-Based Functional Screening Identified Ribosomal Protein L31 that Modulates Prostate Cancer Cell Growth via p53 Pathway
Investigators performed short hairpin RNA-mediated functional screening to identify genes involved in bicalutamide-mediated effects on LNCaP prostate cancer cells. Protein levels of the tumor suppressor p53 and its targets, p21 and MDM2, were increased in LNCaP and bicalutamide-resistant LNCaP cells treated with RPL31 small interfering RNA. [PLoS One] Full Article

AZD1152-HQPA Induces Growth Arrest and Apoptosis in Androgen-Dependent Prostate Cancer Cell Line (LNCaP) via Producing Aneugenic Micronuclei and Polyploidy
Researchers investigated the effects of Aurora B inhibitor, AZD1152-HQPA, on survival and proliferation of androgen receptor-positive prostate cancer cells. They explored the effects of AZD1152-HQPA on cell viability, DNA content, micronuclei formation, and expression of genes involved in apoptosis and cell cycle. [Tumor Biol] Abstract

Zoledronic Acid Increases Cytotoxicity by Inducing Apoptosis in Hormone and Docetaxel-Resistant Prostate Cancer Cell Lines
Researchers investigated the possible synergistic/additive cytotoxic and apoptotic effects of combination of docetaxel and zoledronic acid in PC-3 hormone-refractory prostate cancer cells as well as their docetaxel-resistant sublines. [Tumor Biol] Abstract

LSD1 Controls Metastasis of Androgen-Independent Prostate Cancer Cells through PXN and LPAR6
Investigators show that depletion of lysine-specific demethylase 1 (LSD1) leads to increased migration and invasion of androgen-independent prostate cancer cells. Transcriptome and cistrome analyses reveal that LSD1 regulates expression of lysophosphatidic acid receptor 6 (LPAR6) and cytoskeletal genes including the focal adhesion adaptor protein paxillin (PXN). [Oncogenesis] Full Article


Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Mode
Investigators aimed to validate noncastrate metastatic prostate cancer (NCMPC) risk groups in a recently diagnosed population and to develop a more sensitive prognostic model. NCMPC patients were randomized to receive continuous androgen deprivation therapy with or without docetaxel in the GETUG-15 Phase III trial.
[Eur Urol]

Phase I, Dose-Escalation Study of the Targeted Cytotoxic LHRH Analog AEZS-108 in Patients with Castration- and Taxane-Resistant Prostate Cancer
The Phase I study determined the maximum tolerated dose of AEZS-108 in men with taxane- and castration-resistant prostate cancer while providing additional information on the safety profile and efficacy of this agent. [Clin Cancer Res] Abstract

ProstaCult™: Serum-Free, BPE-Free Medium for Mouse Prostate Colony Assays FREE Sample Request
Secreted Phospholipases A2 in Cancer: Diverse Mechanisms of Action
Several secreted phospholipases A2s (sPLA2s) have been associated with various cancers, including prostate, colon, gastric, lung and breast cancers, yet, their role is controversial and seems to be dependent on the cancer type, the local microenvironment and the enzyme studied. The authors highlight the newest findings on the biological roles of sPLA2s in cancer, with emphasis on their diverse mechanisms of action. [Biochimie] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.
MDxHealth’s ConfirmMDx Genes Identify Prostate Cancer Aggressiveness in Diagnostic Biopsies
MDxHealth SA announced positive data from a study confirming the ability of the ConfirmMDx® genes to identify prostate cancer aggressiveness in diagnostic biopsies. [Press release from MDxHealth SA discussing research to be presented at the European Association of Urology, Section Urological Research (ESUR) Meeting, Glasgow] Press Release

From our sponsor:
Interested in assays for human mammary stem and progenitor cells?
Request your free wallchart.
VolitionRx Announces Prostate Cancer Study
VolitionRx Limited announced a study with The University of Texas MD Anderson Cancer Center’s Department of Genitourinary Medical Oncology. The study will examine the competency of VolitionRx NuQ® assays to distinguish anaplastic prostate cancer, a particularly aggressive form of the disease, from typical castration-resistant prostate cancer. [VolitionRx Limited] Press Release

Metamark Announces Nationwide Availability of ProMark™ Prostate Cancer Test, First-of-Its-Kind Protein-Based Prognostic Test
Metamark announced the nationwide availability of ProMark™, the first-of-its-kind protein-based biopsy test designed to improve the accuracy of prognosis for men diagnosed with prostate cancer.
[Metamark Genetics, Inc.]
Press Release
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Goodbye Flat Biology: 3D Models and the Tumor Microenvironment
November 2-5, 2014
Berlin, Germany

NEW CIRM Showcase: Accelerating Stem Cell Treatments to Patients
November 5, 2014
San Francisco, United States

Visit our events page to see a complete list of events in the prostate cell community.
NEW Physician Scientist – Prostate Cancer Genomics (University of Chicago)

NEW Tenure Track Position – Cancer Biology (Wake Forest Baptist Medical Center)

Postdoctoral Position – Bioinformatics for Prostate Cancer (CRUK Manchester Institute)

Postdoctoral Scholar – Molecular Mechanisms Underlying Tumor Cell Invasion and Metastasis (Case Western Reserve University)

Postdoctoral Positions – Prostate Biology and Cancer Cell and Molecular Biology (State University of Campinas)

Research Assistant – Clinical Prostate Cancer Research Group (Garvan Institute of Medical Research)

Postdoctoral Fellows and Graduate Student Positions (Vancouver Prostate Centre)

Postdoctoral Positions – Prostate Metastasis Evolution (Cold Spring Harbor Laboratory)

Postdoctoral Fellowship Position – Cancer Immunology (Cornell University)

Scientist – Prostate Cell Research (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Prostate Cell News: Archives | Events | Contact Us